Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Clinical pharmacology and therapeutics [Clin Pharmacol Ther] NLMUID: 0372741"" wg kryterium: JN


Tytuł :
A Useful and Sustainable Role for N-of-1 Trials in the Healthcare Ecosystem.
Autorzy :
Selker HP; Tufts Clinical and Translational Science Institute (CTSI), Tufts Medical Center, Boston, Massachusetts, USA.; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.
Cohen T; Tufts Clinical and Translational Science Institute (CTSI), Tufts Medical Center, Boston, Massachusetts, USA.; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.
D'Agostino RB; Department of Mathematics and Statistics, Boston University, Boston, Massachusetts, USA.; Baim Institute for Clinical Research, Boston, Massachusetts, USA.
Dere WH; Department of Internal Medicine, Utah Center for Clinical and Translational Science, University of Utah, USA.; University of Utah School of Medicine, Salt Lake City, Utah, USA.
Ghaemi SN; Psychiatry, Tufts University School of Medicine, Boston, MA, USA.; Psychiatry, Harvard Medical School, Boston, MA, USA.
Honig PK; Pfizer, Collegeville, Pennsylvania, USA.
Kaitin KI; Tufts Center for the Study of Drug Development, Tufts University, Boston, Massachusetts, USA.
Kaplan HC; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Kravitz RL; Department of Internal Medicine, University of California, Davis, Davis, California, USA.
Larholt K; Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
McElwee NE; Health Economics and Outcomes Research, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.
Oye KA; Department of Political Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.; Center for Biomedical Innovation, Cambridge, Massachusetts, USA.
Palm ME; Tufts Clinical and Translational Science Institute (CTSI), Tufts Medical Center, Boston, Massachusetts, USA.; Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.
Perfetto E; Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.; National Health Council, Washington, DC, USA.
Ramanathan C; East Coast Innovation Center, Bayer, Cambridge, Massachusetts, USA.
Schmid CH; Department of Biostatistics, Brown University, Providence, Rhode Island, USA.
Seyfert-Margolis V; My Own Med Inc, Bethesda, Maryland, USA.
Trusheim M; Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Eichler HG; Hans-Georg Eichler, MD, Regulatory Science and Innovation Task Force, European Medicines Agency (EMA), and Medical University of Vienna, The Netherlands, Vienna, Austria.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 22. Date of Electronic Publication: 2021 Sep 22.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility Study.
Autorzy :
Jemielita T; Biostatistics and Research Decision Sciences (BARDS), Merck & Co., Inc., Kenilworth, NJ, USA.
Widman L; Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Fox C; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
Salomonsson S; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
Liaw KL; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
Pettersson A; Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.; Department of Pelvic Cancer, Cancer Theme, Karolinska University Hospital, Stockholm, Sweden.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 22. Date of Electronic Publication: 2021 Sep 22.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Diversity and Inclusion in Drug Development: Rethinking Intrinsic and Extrinsic Factors with Patient Centricity.
Autorzy :
Venkatakrishnan K; EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts, USA.
Benincosa LJ; EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, Massachusetts, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 22. Date of Electronic Publication: 2021 Sep 22.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Lymphocyte profile and immune checkpoint expression in drug-induced liver injury: an immunophenotyping study.
Autorzy :
Cueto-Sanchez A; Servicio de Farmacología Clínica, UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
Niu H; Servicio de Farmacología Clínica, UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
Del Campo-Herrera E; Servicio de Farmacología Clínica, UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
Robles-Díaz M; Servicio de Farmacología Clínica, UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
Sanabria-Cabrera J; Servicio de Farmacología Clínica, UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.; Platform ISCiii for Clinical Research and Clinical Trials UICEC-IBIMA, Malaga, Spain.
Ortega-Alonso A; Servicio de Farmacología Clínica, UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
Garcia-Cortes M; Servicio de Farmacología Clínica, UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
Gonzalez-Grande R; Servicio de Aparato Digestivo, IBIMA, Hospital Universitario Regional de Málaga, Málaga, Spain.
Jimenez-Perez M; Servicio de Aparato Digestivo, IBIMA, Hospital Universitario Regional de Málaga, Málaga, Spain.
Ruiz-Cabello F; Servicio de Análisis Clínicos e Inmunología, UGC de Laboratorio Clínico, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Andrade RJ; Servicio de Farmacología Clínica, UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
Lucena MI; Servicio de Farmacología Clínica, UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.; Platform ISCiii for Clinical Research and Clinical Trials UICEC-IBIMA, Malaga, Spain.
Stephens C; Servicio de Farmacología Clínica, UGC Aparato Digestivo, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.; Centro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 20. Date of Electronic Publication: 2021 Sep 20.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Corrigendum: Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drug-Gene Interactions for Commonly Used Drugs.
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 17. Date of Electronic Publication: 2021 Sep 17.
Typ publikacji :
Published Erratum
Tytuł :
Evolving acceptance and use of RWE for regulatory decision-making on the benefit/risk assessment of a drug in Japan.
Autorzy :
Nishioka K; Office of New Drug III, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Makimura T; Office of Standards and Compliance for Medical Devices, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Ishiguro A; Office of Research Promotion, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Nonaka T; Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Yamaguchi M; Office of Non-clinical and Clinical Compliance, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Uyama Y; Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 16. Date of Electronic Publication: 2021 Sep 16.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Population pharmacokinetics and pharmacodynamics of the neutralizing antibodies bamlanivimab and etesevimab in patients with mild to moderate COVID-19 infection.
Autorzy :
Chigutsa E; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, 46285.
O'Brien L; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, 46285.
Ferguson-Sells L; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, 46285.
Long A; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, 46285.
Chien J; Global PK/PD & Pharmacometrics, Eli Lilly and Company, Indianapolis, 46285.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 12. Date of Electronic Publication: 2021 Sep 12.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid (siRNA), on Cytochrome P450 Activity in Liver.
Autorzy :
Vassiliou D; Centre for Inherited Metabolic Diseases (CMMS), Porphyria Centre Sweden, Karolinska University Hospital, Stockholm, Sweden.; Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden.; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Sardh E; Centre for Inherited Metabolic Diseases (CMMS), Porphyria Centre Sweden, Karolinska University Hospital, Stockholm, Sweden.; Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden.; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Harper P; Centre for Inherited Metabolic Diseases (CMMS), Porphyria Centre Sweden, Karolinska University Hospital, Stockholm, Sweden.; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Simon AR; Alnylam Pharmaceuticals, Cambridge, MA, USA.
Clausen VA; Alnylam Pharmaceuticals, Cambridge, MA, USA.
Najafian N; Alnylam Pharmaceuticals, Cambridge, MA, USA.
Robbie GJ; Alnylam Pharmaceuticals, Cambridge, MA, USA.
Agarwal S; Alnylam Pharmaceuticals, Cambridge, MA, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 12. Date of Electronic Publication: 2021 Sep 12.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Risk of Heart Failure in Rheumatoid Arthritis Patients Treated with Tumour Necrosis Factor-α Inhibitors.
Autorzy :
Chen HK; School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Shao SC; School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Weng MY; Department of Internal Medicine, Division of Allergy, Immunology, and Rheumatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Lin SJ; Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA.
Hung MJ; College of Medicine, Chang Gung University, Taoyuan, Taiwan.; Section of Cardiology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Chan YY; Department of Pharmaceutical Materials Management, Chang Gung Medical Foundation, Taoyuan, Taiwan.
Lai EC; School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 08. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Expanding Approved Patient Populations for Rare Disease Treatment Using in vitro Data.
Autorzy :
Weaver JL; Office of Clinical Pharmacology/OTS/CDER/FDA.
Wu W; Office of Clinical Pharmacology/OTS/CDER/FDA.
Hyland PL; Office of Clinical Pharmacology/OTS/CDER/FDA.
Lim R; Office of Immunology & Inflammation/OND/CDER/FDA.
Smpokou P; Office of Rare Diseases, Pediatrics, Urologic, and Reproductive Medicine, OND/CDER/FDA.
Pacanowski M; Office of Clinical Pharmacology/OTS/CDER/FDA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 08. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients.
Autorzy :
Stader F; Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Battegay M; Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Sendi P; Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.; Institute for Infectious Diseases, University of Bern, Bern, Switzerland.
Marzolini C; Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 08. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Overcoming Barriers to Biosimilar Adoption: Commentary on "Cost to Medicare of Delayed Adalimumab Biosimilar Availability".
Autorzy :
Arad N; Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina, USA.
Kroetsch A; Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina, USA.
McClellan M; Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 06. Date of Electronic Publication: 2021 Sep 06.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail.
Autorzy :
Lenoir C; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.
Terrier J; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.
Gloor Y; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.
Curtin F; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Personalized Health and Related Technologies, Swiss Federal Institute of Technology in Zurich, Zurich, Switzerland.
Rollason V; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Desmeules JA; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Daali Y; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Reny JL; Division of General Internal Medicine, Department of Medicine, Geneva University Hospitals, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Samer CF; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 02. Date of Electronic Publication: 2021 Sep 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Identifiability of biologicals: an analysis using the EMA adverse drug reaction database, EudraVigilance.
Autorzy :
Pinheiro LC; European Medicines Agency (EMA) Amsterdam, Amsterdam, The Netherlands.
Giezen TJ; Foundation Pharmacy for Hospitals in Haarlem, Haarlem, The Netherlands.; Medicines Evaluation Board, Utrecht, The Netherlands.; Biosimilar Medicinal Products Working Party (BMWP), European Medicines Agency.
Wolff-Holz E; Biosimilar Medicinal Products Working Party (BMWP), European Medicines Agency.; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany.
Weise M; Biosimilar Medicinal Products Working Party (BMWP), European Medicines Agency.; Paul-Ehrlich-Institut, Langen, Germany.; Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency.
Laslop A; Bundesamt für Sicherheit im Gesundheitswesen (BASG), Vienna, Austria.; Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency.
Hidalgo-Simon A; European Medicines Agency (EMA) Amsterdam, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 02. Date of Electronic Publication: 2021 Sep 02.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network.
Autorzy :
Giacomini KM; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Karnes JH; Department of Pharmacy Practice and Science, University of Arizona College of Pharmacy, Tucson, Arizona, USA.
Crews KR; Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Monte AA; Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Murphy WA; Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Oni-Orisan A; Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA.
Ramsey LB; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.; Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.
Yang JJ; Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Whirl-Carrillo M; Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, California, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep; Vol. 110 (3), pp. 559-562. Date of Electronic Publication: 2021 Jul 28.
Typ publikacji :
Journal Article
MeSH Terms :
Pharmacogenetics/*methods
Precision Medicine/*methods
Humans ; Research
Czasopismo naukowe
Tytuł :
Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma.
Autorzy :
Ferron-Brady G; GlaxoSmithKline, Collegeville, PA, USA.
Rathi C; GlaxoSmithKline, Collegeville, PA, USA.
Collins J; GlaxoSmithKline, Research Triangle Park, NC, USA.
Struemper H; GlaxoSmithKline, Research Triangle Park, NC, USA.
Opalinska J; GlaxoSmithKline, Collegeville, PA, USA.
Visser S; GlaxoSmithKline, Collegeville, PA, USA.
Jewell RC; GlaxoSmithKline, Research Triangle Park, NC, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep 01. Date of Electronic Publication: 2021 Sep 01.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram.
Autorzy :
Bråten LS; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.; Department of Life Sciences and Health, Faculty of Health Sciences, OsloMet - Oslo Metropolitan University, Oslo, Norway.
Haslemo T; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.; Department of Life Sciences and Health, Faculty of Health Sciences, OsloMet - Oslo Metropolitan University, Oslo, Norway.
Jukic MM; Section of Pharmacogenetics, Department of Physiology and Pharmacology, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden.; Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Ivanov M; Copenhagen Plant Science Centre, Department of Plant and Environmental Sciences, University of Copenhagen, Copenhagen, Denmark.
Ingelman-Sundberg M; Section of Pharmacogenetics, Department of Physiology and Pharmacology, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden.
Molden E; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.; Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway.
Kringen MK; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.; Department of Life Sciences and Health, Faculty of Health Sciences, OsloMet - Oslo Metropolitan University, Oslo, Norway.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep; Vol. 110 (3), pp. 786-793. Date of Electronic Publication: 2021 Apr 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Aryl Hydrocarbon Hydroxylases/*genetics
Citalopram/*metabolism
Cytochrome P-450 CYP2C19/*genetics
Haplotypes/*genetics
Adult ; Female ; Genotype ; Homozygote ; Humans ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Genome-Wide Approach to Measure Variant-Based Heritability of Drug Outcome Phenotypes.
Autorzy :
Muhammad A; Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Aka IT; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Birdwell KA; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Gordon AS; Department of Pharmacology, Northwestern University, Chicago, Illinois, USA.; Center for Genetic Medicine, Northwestern University, Chicago, Illinois, USA.
Roden DM; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Wei WQ; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Mosley JD; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Van Driest SL; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep; Vol. 110 (3), pp. 714-722. Date of Electronic Publication: 2021 Jul 12.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Genetic Variation/*genetics
Pharmaceutical Preparations/*administration & dosage
Adult ; Bayes Theorem ; Female ; Genome-Wide Association Study/methods ; Humans ; Male ; Middle Aged ; Pharmacogenomic Testing/methods ; Phenotype
Czasopismo naukowe
Tytuł :
Drug-Drug-Gene Interactions: A Call for Clinical Consideration.
Autorzy :
Bruckmueller H; Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Pharmacy, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Cascorbi I; Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep; Vol. 110 (3), pp. 549-551. Date of Electronic Publication: 2021 Jul 18.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Interactions/*genetics
Drug Labeling/standards ; Drug Prescriptions/standards ; Humans
Czasopismo naukowe
Tytuł :
Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates.
Autorzy :
Jukić MM; Section of Pharmacogenetics, Department of Physiology and Pharmacology, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden.; Department of Physiology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
Smith RL; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.
Molden E; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway.; Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway.
Ingelman-Sundberg M; Section of Pharmacogenetics, Department of Physiology and Pharmacology, Biomedicum 5B, Karolinska Institutet, Stockholm, Sweden.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Sep; Vol. 110 (3), pp. 750-758. Date of Electronic Publication: 2021 May 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antipsychotic Agents/*therapeutic use
Aripiprazole/*therapeutic use
Cytochrome P-450 CYP2D6/*genetics
Haplotypes/*genetics
Risperidone/*therapeutic use
Venlafaxine Hydrochloride/*therapeutic use
Adult ; Alleles ; Female ; Genotype ; Humans ; Male ; Middle Aged ; Phenotype ; Retrospective Studies
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies